• 09.08.16

    Peter Goss Analyzes New Jersey Summary Judgment Order in Talc Suits against Johnson & Johnson

    Peter Goss was quoted in Law360’s analysis of a recent New Jersey trial court ruling in the Johnson & Johnson talc litigation. The order excluded the plaintiffs’ experts’ testimony and dismissed the claims of two women who alleged that exposure to bath talc caused their ovarian cancer. (“J&J Talc Suits Show Evidence Standards Vary Among Courts,” available with subscription here.) The decision contrasts with the eight-figure verdicts against Johnson & Johnson in recent trials of talc cases in St. Louis. Goss explained that the different outcomes are partly due to different standards for evaluating expert testimony: "Even though New Jersey…
  • 08.29.16

    Peter Goss Comments on Emerging Appellate Split on Generic Drug Preemption

    Peter Goss commented for Law360 on a recent ruling by the New Jersey Supreme Court finding no federal preemption where the generic drug manufacturer’s label for metoclopramide (Reglan) did not match that of the brand.  (“NJ Reglan Ruling Widens Generic Label Preemption Split,” available with subscription here.)  Goss noted that the decision conflicted with Fifth and Sixth Circuit rulings that failure-to-warn claims against generic Reglan manufacturers were preempted, even though the generic and brand labels did not match.  “This could mean that at some point, the U.S. Supreme Court is going to need to resolve the split,” Goss noted.   Mr. Goss focuses his…
  • 06.02.16

    Peter Goss Discusses FDA Approval of New Implant for Opioid Addiction Treatment

    Peter J. Goss was interviewed by Law360 for an article analyzing the FDA’s recent approval of an implantable version of an opioid addiction drug, Probuphine.  (“FDA's Opioid Implant Nod Shows Pressure To Curb Addiction,” available to Law360 subscribers here.)  Goss noted that the FDA has been under pressure to curb the opioid abuse epidemic, and that the approval of the Probuphine implant adds “one more tool … to the overall toolkit physicians will have for treating opioid addicts.” Mr. Goss focuses his national practice on pharmaceutical and medical device product liability litigation and toxic torts. He has represented global pharmaceutical, medical technology, and chemical firms in hundreds…
  • 11.19.15


    Blackwell Burke P.A. has been included on the 2016 U.S. News & World Report and Best Lawyers Best Law Firms list with a ranking of Metropolitan Tier 1 for Products Liability Litigation – Defendant, and a Tier 2 ranking under Mass Tort Litigation/Class Actions – Defendants.The U.S. News – Best Lawyers "Best Law Firms" rankings are based on a rigorous evaluation process that includes the collection of client and lawyer evaluations, peer review from leading attorneys, and review of additional information provided by law firms as part of the formal submission process.  Feedback was obtained from clients in various areas,…
  • 11.15.15


    Blackwell Burke P.A. has been ranked as “Highly Recommended” in the 2016 Edition of Benchmark Litigation, one of just eight Minnesota firms to receive that recognition.  Firm Founder and CEO Jerry Blackwell, partners Corey Gordon, Peter Goss, Benjamin Hulse, and special counsel Mike Hatch have all been named Minnesota Litigation Stars.  Partner Mary Young was named a Minnesota Future Star.“Highly Recommended” firms are those consistently acknowledged by clients and competitors and held as dominant in their particular jurisdiction during Benchmark Litigation’s six-month research process.  Blackwell Burke also was ranked “Highly Recommended” in the 2015 Edition of Benchmark Litigation.   The “Litigation…
  • 10.01.15

    Peter Goss Shares Advice on Avoiding Attorney-Client Privilege Blunders

    RE: Website UpdatePeter J. Goss recently commented for a Law360 article entitled “The 3 Biggest Blunders With Attorney-Client Privilege.”  Goss cautioned that written memoranda containing advice on changes to business practices are often difficult or impossible to “claw back” after inadvertent disclosure.  These memoranda can prove troublesome when they recommend a course of action that the company ultimately decides not to take.  For that reason, Goss recommends that lawyers confer closely with the affected businesspeople before reducing their advice to writing.  “This is important for the lawyers involved in generating a piece of writing that could affect a course of…

Interested in learning more?

Email Disclaimer Close

Sending us an email will not make you a client of our firm. Until we have agreed to represent you, nothing you send us will be confidential or privileged.

If your email is related to representation, the best way for you to inquire about a possible representation is to call a Blackwell Burke P.A. attorney at one of the telephone numbers listed on our Attorney's page. An attorney will first take you through our conflict of interest procedure and see that you are put in touch with the lawyer best suited to handle your matter.

If you proceed with an email, you confirm that you have read and understand this notice. To proceed, click I Agree.